Skip to Content
Merck
CN

SRP3029

EG-VEGF human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Synonym(s):

Endocrine Gland-derived Vascular Endothelial Growth Factor, PROK1, Prokineticin 1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.32
UNSPSC Code:
12352202
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

human

recombinant

expressed in E. coli

assay

≥98% (HPLC), ≥98% (SDS-PAGE)

form

lyophilized

mol wt

9.6 kDa

packaging

pkg of 20 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white to off-white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... PROK1(84432)

General description

EG-VEGF (endocrine gland-derived vascular endothelial growth factor) belongs to the prokineticin family. It is mainly expressed in the steroidogenic glands (ovary, testis, adrenal cortex and placenta). EG-VEGF is a small, secreted peptide and works as a tissue-specific pro-angiogenic mitogen and chemotactic agent. The gene is mapped to human chromosome 1p13.
Recombinant human EG-VEGF is a 9.6kDa protein consisting of 86 amino acid residues and ten cysteine residues that potentially form five pairs of intra-molecular disulfide bonds.

Biochem/physiol Actions

EG-VEGF (endocrine gland-derived vascular endothelial growth factor) is involved in angiogenesis, inflammatory responses and hematopoiesis. It also participates in female reproduction. EG-VEGF suppresses trophoblast invasion in pregnancy. Changes in the activity of this protein are associated with gestational complication, such as gestational trophoblastic diseases, repeated pregnancy losses, preeclampsia and intrauterine fetal growth restriction. EG-VEGF interacts with G protein-coupled receptors, prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2). It is also involved in the pathology of Leydig-cell-tumors, papillary thyroid cancer, neuroblastoma, prostate cancer, gastrointestinal tumors, pancreatic ductal adenocarcinoma, Merkel cell carcinoma and multiple myeloma.

Physical form

Lyophilized with no additives.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

MHPIPDSSPL LQFGGQVRQR YLYTDDAQQT EAHLEIREDG TVGGAADQSP ESLLQLKALK PGVIQILGVK TSRFLCQRPD GALYGSLHFD PEACSFRELL LEDGYNVYQS EAHGLPLHLP GNKSPHRDPA PRGPARFLPL PGLPPALPEP PGILAPQPPD VGSSDPLSMV GPSQGRSPSY AS


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library